Study the Effects of a therapeutic method on limb spasticity in cerebral stroke

Clinical trial of studying the effects of shock wave therapy on upper limb spasticity in patients with cerebral stroke

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013052313434N1

Enrollment

Registered

2013-11-27

Start date

2013-03-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Stroke. Condition 2: Spasm. Stroke, not specified as haemorrhage or infarction Cramp and spasm

Interventions

Intervention 1: In placebo step, shock wave device probe will be put on forearm's flexor muscles (flexor carpi ulnaris and radialis) and in arm's region on biceps muscle and also on hand's interosseou

Placebo

Treatment - Devices

In placebo step, shock wave device probe will be put on forearm's flexor muscles (flexor carpi ulnaris and radialis) and in arm's region on biceps muscle and also on hand's interosseous muscles. Simul

In active treatment step, device probe will be put on biceps muscle with 1000 shots and 0.069 mj/mm2 intensity, on forearm muscles with 1500 shots and 0.03 mj/ml2 intensity and on intraosseous muscles

Eligibility

Sex/Gender

All

Age

16 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: At least 6 months after the last stroke; upper limb spasticity more than 2 based on modified modified Ashworth Scale; not receiving GABAergic and antispasmodic during the study. Exclusion criteria: History of botulinum toxin injection or receiving phenol or alcohol in past nine months; history of surgeries in related limbs; physiotherapy and occupational therapies in upper limbs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Modified modified Ashworth scale. Timepoint: Before and after placebo treatment, before and after active treatment, Four weeks after active treatment. Method of measurement: By examiner.;Timing for Nine hole pig test. Timepoint: Before and after placebo treatment, before and after active treatment, Four weeks after active treatment. Method of measurement: Chronometer.;Branstran's treatment steps. Timepoint: Before and after placebo treatment, before and after active treatment, Four weeks after active treatment. Method of measurement: By examiner.;Hoffmann reflex. Timepoint: Before and after placebo treatment, before and after active treatment, Four weeks after active treatment. Method of measurement: EMG-NCV.;H/M ratio. Timepoint: Before and after placebo treatment, before and after active treatment, Four weeks after active treatment. Method of measurement: EMG-NCV.	—

Measure

Time frame

Modified modified Ashworth scale. Timepoint: Before and after placebo treatment, before and after active treatment, Four weeks after active treatment. Method of measurement: By examiner.;Timing for Nine hole pig test. Timepoint: Before and after placebo treatment, before and after active treatment, Four weeks after active treatment. Method of measurement: Chronometer.;Branstran's treatment steps. Timepoint: Before and after placebo treatment, before and after active treatment, Four weeks after active treatment. Method of measurement: By examiner.;Hoffmann reflex. Timepoint: Before and after placebo treatment, before and after active treatment, Four weeks after active treatment. Method of measurement: EMG-NCV.;H/M ratio. Timepoint: Before and after placebo treatment, before and after active treatment, Four weeks after active treatment. Method of measurement: EMG-NCV.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Seyedeh Somayeh Daliri

Tehran University of Medical Sciences

dr_daliri79@yahoo.com+98 21 4447 3383

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026